The National Cancer Institute invites applications for its physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional) funding opportunity. This supports transdisciplinary and translational research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival.
Research applications should test the effects of physical activity, alone or in combination with weight control, on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin or glucose metabolism, especially those obtained from tumour tissue sourced from repeat biopsies where available.
Applications should use experimental designs, such as randomised controlled clinical trials, fractional factorial designs, and include transdisciplinary approaches that bring together behavioural intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.
This opportunity uses the R21 Exploratory/Developmental Research Grants funding mechanism.
Funding & Duration
The combined budget for direct costs for the two-year project period may not exceed USD $275,000 (approx. AUD $378,000). No more than USD $200,000 (approx. AUD $275,000) may be requested in any single year.
The maximum project period is two years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- Applications must be submitted for internal review by 2 October 2018
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review